Search

everythinglearnresearchcommunity

for

Search:↓

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.

JAK inhibitors are effective treatments for alopecia areata.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

CD8+ T cells play a key role in graft-versus-host disease in certain mice models.

In alopecia areata, certain immune cells increase and express a protein linked to immune activation.

New micelle nanocarriers deliver Tacrolimus more effectively to skin layers for psoriasis treatment than the current Protopic ointment.

New treatments for cancer and skin disorders show promise in disrupting harmful cell interactions and promoting hair growth.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Inhibiting TYK2 can restore hair growth in alopecia areata.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

Retinoids or their analogs could treat skin pigmentation disorders like melasma and vitiligo.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Mouse models help target specific genes in lymphatic cells for research.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

Cancer cells often have more copies of TERT and TERC genes, which helps them grow and could affect patient outcomes.

HOTTIP and miR-10b contribute to glioma therapy resistance by affecting cell behavior, suggesting they could be targets for treatment.